Using the publicly available data of The Cancer Genome Atlas (TCGA) and single-cell (sc) profiling of breast cancer (GSE161529), our data demonstrate that high expression of SLAMF6 in the tumor correlates with better patient survival and elevated immune activity in breast cancer and melanoma. Here, SLAMF6 is linked to melanoma.